|
MediciNova Reports Third Quarter 2012 Results and Update on MN-221 …
NASDAQ The decrease in research and development expenses was mainly due to a decrease in spending on MN-221 due to the completion of the MN-221-CL-007 trial in patients with acute exacerbations of asthma, partially offset by an increase in spending on our … MediciNova Says Considering Cost, Timing and Design of Future Trials; FDA … |
View full post on asthma – Google News